• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Galmed Pharmaceuticals Ltd.

    9/20/24 2:17:11 PM ET
    $GLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLMD alert in real time by email
    SC 13G 1 o920241sc13g.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.   )*

     

    GALMED PHARMACEUTICALS LTD.
    (Name of Issuer)
     
    Ordinary Share
    (Title of Class of Securities)

     

      M47238122  
      (CUSIP Number)  
     
    September 18,2024
    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)
         
      x Rule 13d-1(c)
         
      ¨ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 6 
     

     

    CUSIP No.  60879E200
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    MASAYA OTSUKA

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a)¨

    (b)¨

    3

    SEC® USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    JAPAN

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    63,761Shares

    6

    SHARED VOTING POWER

     

    0 Shares

    7

    SOLE DISPOSITIVE POWER

     

    63,761Shares

    8

    SHARED DISPOSITIVE POWER

     

    0 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    63,761Shares

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

     

     Page 2 of 6 
     

     

    Item 1(a). Name of Issuer:
       
      Galmed Pharmaceuticials Ltd.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
      16 Tiomkin Street, Tel Aviv, Israel, 6578317
       
    Item 2(a). Name of Person Filing:
       
      MASAYA OTSUKA
       
    Item 2(b). Address of Principal Business Office or, if none, Residence:
       
     

    Yukarigaoka Miyanodai Haitsu #314

    1-3-1 Miyanodai, Sakura-shi,Chiba-ken,285-0857, JAPAN

       
    Item 2(c). Citizenship:
       
      JAPAN
       
    Item 2(d). Title of Class of Securities:
       
      Ordinary Shares
       
    Item 2(e). CUSIP Number:  M47238122

     

     Page 3 of 6 
     

     

    Item 3. If this Statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
      (g) ¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
      (j) ¨ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:      

     

    Item 4. Ownership.
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount Beneficially Owned: 63,761
      (b) Percent of Class: 9.9%
      (c) Number of shares as to which such person has:
        (i) sole power to vote or to direct the vote: 63,761
        (ii) shared power to vote or to direct the vote: 0
        (iii) sole power to dispose or to direct the disposition of: 63,761
        (iv) shared power to dispose or to direct the disposition of: 0

     

     Page 4 of 6 
     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.
       
     Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
      Not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.
       
      Not applicable.
       
    Item 9. Notice of Dissolution of Group.
       
      Not applicable.
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect for the time being.

     

     Page 5 of 6 
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: September 20,2024 MASAYA OTSUKA
       
       
      /s/ MASAYA OTSUKA  
      Name: MASAYA OTSUKA  
      Title: Individual  

     

     

    Page 6 of 6

     

     

     

    Get the next $GLMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GLMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GLMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

      Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic drivers, unlocking potential new commercial and clinical pathways.Validated decrease in ANP (Atrial Natriuretic Peptide), a key clinical marker for heart failure, highlights expansion potential into broader cardiometabolic markets.Strategic collaboration with Proteas Health positions Galmed at the forefront of AI-driven biomarker-guided therapeutics.TEL AVIV, Israel, May 27, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for the treatment of liver, cardiometabolic diseases and GI

      5/27/25 8:00:00 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      TEL AVIV, Israel, May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three months ended March 31, 2025 and recent developments. Key Recent Developments Announced First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer ModelsSigned Term Sheet for the Development of Novel Semaglutide Sublingual FormulationRaised $6.5 million since the beginning of 2025. Company's current cash balance is $20.1 millionFinancial Summary – First Quarter 2025 vs. First Quarte

      5/22/25 8:00:00 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models

      Aramchol, an SCD1 inhibitor, significantly attenuates and prevents biliary fibrosis in mouse models of primary sclerosing cholangitis (PSC)Aramchol treatment leads to significant inhibition (2-fold, p<0.05) of TGFβ-induced hepatic fibrosis pathways while upregulating peroxisome proliferator activated receptor (PPAR) signalingAramchol's effect in the prevention and treatment of biliary and hepatic fibrosis, provides the rationale for assessing Aramchol in further clinical studies in patients with fibrosis driven liver cancersTEL AVIV, Israel, May 13, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardi

      5/13/25 8:00:00 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLMD
    SEC Filings

    See more
    • SEC Form 6-K filed by Galmed Pharmaceuticals Ltd.

      6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)

      5/27/25 8:15:28 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Galmed Pharmaceuticals Ltd.

      6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)

      5/22/25 8:00:17 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Galmed Pharmaceuticals Ltd.

      6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)

      5/13/25 8:24:24 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity reiterated coverage on Galmed Pharmaceuticals with a new price target

      Canaccord Genuity reiterated coverage of Galmed Pharmaceuticals with a rating of Buy and set a new price target of $21.00 from $20.00 previously

      5/17/21 10:09:42 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Galmed Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Galmed Pharmaceuticals with a rating of Buy and set a new price target of $25.00 from $29.00 previously

      3/19/21 6:22:00 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Galmed Pharmaceuticals Ltd.

      SC 13G/A - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)

      11/14/24 12:24:34 PM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Galmed Pharmaceuticals Ltd.

      SC 13G/A - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)

      9/20/24 2:18:08 PM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Galmed Pharmaceuticals Ltd.

      SC 13G - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)

      9/20/24 2:17:11 PM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLMD
    Financials

    Live finance-specific insights

    See more
    • Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      TEL AVIV, Israel, May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three months ended March 31, 2025 and recent developments. Key Recent Developments Announced First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer ModelsSigned Term Sheet for the Development of Novel Semaglutide Sublingual FormulationRaised $6.5 million since the beginning of 2025. Company's current cash balance is $20.1 millionFinancial Summary – First Quarter 2025 vs. First Quarte

      5/22/25 8:00:00 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

      TEL AVIV, Israel, June 1, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver and fibro-inflammatory diseases reports financial results for the three months ended March 31, 2023 and recent developments Recent Developments Initiated a new clinical program to evaluate its lead compound, Aramchol meglumine for the treatment of Primary Sclerosing Cholangitis (PSC), a rare disease for which there is no approved treatment;Phase 2 proof of concept PSC study to be conducted in collaboration with the Stravitz–Sanyal Institute for Liver Disease and Metabolic Health Virginia Commonwealth University;Formed a str

      6/1/23 8:00:00 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

      TEL AVIV, Israel, Aug. 4, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, fibrosis and other fibrotic indications, provides today a business update and reports financial results for the three and six months ended June 30, 2022. Recent Developments Discontinuing the Open Label Part of the ARMOR study having reached its objectives while refocusing research and development on advancing Aramchol for new anti-fibrotic indications.Implementing a cost reduction plan that includes reduction in headc

      8/4/22 8:00:00 AM ET
      $GLMD
      Biotechnology: Pharmaceutical Preparations
      Health Care